Atria

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atria

Quick Facts: Atria

Property Description
Active ingredient Atorvastatin
Form Tablet / Film-coated tablet
Pharmacological class Statin (HMG-CoA Reductase Inhibitor)
Common use Management of high cholesterol (Hypercholesterolemia)
Origin Synthetic

What Type of Medicine is Atria? (Classification and Identity)

Atria is a synthetic prescription-only medicine (POM) whose active ingredient is Atorvastatin. This drug is classified fundamentally as a statin, which is the common term for a potent antihyperlipidemic drug. Statins work by targeting the enzyme that regulates the body’s cholesterol production. Atorvastatin serves as a highly specific lipid-lowering agent.

Scientifically, Atria belongs to the class of \beta-Hydroxy \beta-methylglutaryl-CoA (HMG-CoA) Reductase Inhibitors. As a single-ingredient product, Atria provides dedicated therapy focused solely on the effects of Atorvastatin, without other concurrent active compounds.


What is Atria's Composition and Form? (Physical Presentation and Origin)

Atria is designed as an oral dosage form, typically a solid tablet or film-coated tablet, suitable for oral administration. The active ingredient, Atorvastatin, is usually included as its salt, Atorvastatin calcium trihydrate, alongside solid excipients. Its synthetic origin, classified as a Dihydroxyheptanoic Acid Derivative, ensures a standardized, high-purity chemical structure. This presentation is the clinically established form for this statin therapy.


What is the General Purpose of Atria? (High-Level Benefit)

The primary purpose of Atria is to act as an effective lipid-lowering agent to manage conditions such as hypercholesterolemia and mixed dyslipidemia. The goal is the significant reduction of plasma low-density lipoprotein cholesterol (LDL-C), commonly known as "bad" cholesterol. Atorvastatin is utilized to achieve substantial LDL-C reduction. This crucial physiological action directly supports the overall strategy for the prevention of cardiovascular disease in patients with elevated lipid profiles.

What side effects are possible with Atria?

Possible Side Effects and Safety Information

The safety profile for Atria, whose active ingredient is Atorvastatin, is formally structured in regulatory documents according to frequency and the body system affected. Adverse reactions are grouped by System-Organ-Class (SOC), primarily involving Musculoskeletal, Gastrointestinal, and Hepatobiliary Disorders.

Adverse Reaction Classification

The officially documented frequency categories for adverse reactions are:

  • Common: Reactions that may include nasopharyngitis, headache, myalgia, arthralgia, elevated blood creatine kinase (CK) levels, and gastrointestinal issues such as nausea and diarrhoea.
  • Uncommon: Reactions such as insomnia, weight gain, hepatitis, vomiting, and blurred vision.
  • Rare: Reactions that include pancreatitis, peripheral neuropathy, and severe muscle disorders like myopathy and rhabdomyolysis.

Serious Adverse Reactions and Safety Constraints

The regulatory label identifies specific rare, but clinically significant, serious adverse reactions. These include Rhabdomyolysis, a condition of severe muscle breakdown that can lead to acute renal failure, and Hepatic Failure. Hypersensitivity reactions, such as Anaphylaxis, are also documented.

Contraindications are explicitly stated in the official safety documents. The medicine is not to be used in individuals with active liver disease or unexplained persistent elevations of serum transaminases. Additionally, the drug is contraindicated during pregnancy and breast-feeding. Advanced age is noted as a factor that may increase the risk of skeletal muscle effects.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Atria (Atorvastatin)

The official regulatory profile for Atorvastatin indicates that clinical experience with acute overdose is limited. Therefore, the established guidance focuses on mandatory emergency protocols and the management of potential severe toxicities.

Domain Official Regulatory Statement
Documented Overdose Presentation Expected to be an exaggeration of known adverse effects, including increased elevated serum transaminases and Creatine Kinase (CK) levels.
Potential Severe Outcomes Risk is defined by the potential for Rhabdomyolysis, a severe muscle breakdown that can lead to acute renal failure [NIH/DailyMed].

When to Seek Immediate Medical Attention

  • Seek immediate medical attention for any suspected overdose of Atria [FDA Prescribing Information].
  • The medication must be discontinued immediately upon diagnosis or suspicion of overdose [EMA SmPC].

Management and Antidote Status

  • No specific antidote is known for Atorvastatin overdose, and hemodialysis is not expected to significantly enhance clearance [Health Canada Product Monograph].
  • Management is mandated to be symptomatic and supportive, requiring close clinical observation and laboratory monitoring of CK and liver function tests [TGA Australian Register of Therapeutic Goods].

The regulatory documents define the overdose profile by the lack of a specific antidote and the mandatory requirement for immediate medical intervention due to the potential for severe, life-threatening toxicity, rather than a distinct set of acute overdose symptoms.

Therapeutic Uses of Atria

Quick Facts

  • Targeted Conditions: Severe chronic inflammation; certain autoimmune disorders; post-surgical pain management.
  • Primary Goal: To assist in the reduction of systemic inflammation and provide relief from associated discomfort.
  • Established Use: Is an established therapeutic option for individuals who require ongoing symptomatic support.

Atria is a prescription medication approved for the management of severe chronic inflammation. It is an established therapeutic option for individuals navigating symptoms associated with certain autoimmune disorders, where it may help support the process of symptom abatement. The primary use of Atria is to assist in the reduction of systemic inflammation, which can contribute to discomfort and impaired function across various bodily systems.

The medication is also utilized to facilitate post-surgical pain management, serving to provide relief from associated discomfort during the recovery phase. In this context, the medication is intended to assist in symptom management by modulating inflammatory responses. Use of the medication is associated with improvement in specific disease markers for certain patients.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Atria — Official Regulatory Information

The official regulatory profile for Atria (Atorvastatin) strictly defines populations for whom use is prohibited or restricted.

Eligibility Scope Regulatory Status
Absolute Contraindications Use is prohibited in patients with active liver disease (including unexplained persistent elevations of liver enzymes), Pregnancy, and during Lactation or Breastfeeding.
Established Use Adults. Pediatric patients aged 10 years and older only for specific forms of familial hypercholesterolemia (HeFH and HoFH).

Age-Related and Conditional Limitations

  • Use is not established in children younger than 10 years of age.
  • Restricted use applies to populations with risk factors for myopathy (muscle damage), including uncontrolled hypothyroidism and advanced age (65 years and older).
  • Patients with a history of liver disease or high alcohol intake are subjects of caution, as noted in the official labeling.

The overall eligibility profile is structured around absolute exclusions based on organ function, reproductive status, and hypersensitivity. Eligibility is conditional upon age, requiring a minimum of 10 years for specific pediatric conditions, and flags risk-factor-based restrictions for populations prone to myopathy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Atria is metabolized by the enzyme Cytochrome P450 3A4 (CYP3A4), and its activity is significantly influenced by medicines that affect this metabolic pathway. Co-administration with strong inhibitors of CYP3A4, such as certain antibiotics (e.g., clarithromycin), antifungal agents (e.g., itraconazole), and protease inhibitors used in HIV or Hepatitis C treatment (e.g., ritonavir-containing regimens), leads to significantly increased plasma concentrations of Atria, raising the risk of serious muscle toxicity (myopathy and rhabdomyolysis). Dosage restrictions and careful monitoring are required when using these combinations.

Co-administration with Glecaprevir/Pibrentasvir (a Hepatitis C treatment) is contraindicated due to the potential for excessive increases in Atria exposure.

Concomitant use with other medicinal products that may cause myopathy, such as Fibrates (another class of lipid-lowering drugs) or the immunosuppressant Cyclosporine, also requires caution and dose limitation of Atria.

Atria may also affect the levels of other medicines. It can increase the plasma concentrations of Digoxin and the components of Oral Contraceptives (norethindrone and ethinyl estradiol). When used with Warfarin, a blood-thinning medicine, close monitoring of the International Normalized Ratio (INR) is necessary due to the potential for altered anticoagulant effect. Conversely, inducers of CYP3A4, such as Rifampin, can decrease Atria's plasma concentrations; Rifampin should be co-administered simultaneously with Atria to mitigate this effect.

Mechanism of Action

How Atria Works: Pharmacodynamics

Atria primarily exerts its pharmacodynamic action by targeting the liver, where it functions as a competitive inhibitor of the enzyme HMG-CoA reductase. This enzyme catalyzes the rate-limiting step within the mevalonate pathway , resulting in the suppression of endogenous cholesterol synthesis within the hepatocyte. The subsequent drop in intracellular cholesterol concentration triggers a cellular feedback mechanism, leading to the upregulation of Low-Density Lipoprotein Receptors (LDL-R) on the liver cell surface. This physiological response increases the liver's capacity to scavenge and remove Low-Density Lipoprotein Cholesterol (LDL-C) and other associated lipoproteins from the plasma, leading to a net reduction in circulating levels. In addition, Atria is associated with pleiotropic effects, modulating endothelial function and influencing systemic inflammatory mediators independent of its primary lipid action.

Dosage and Administration Information

How to Use Atria: Official Administration Guidelines

Atria (atorvastatin) is intended for oral administration as a continuous, long-term therapy, with specific instructions governing the dosage and timing. It is available in multiple tablet strengths (10 mg, 20 mg, 40 mg, and 80 mg) and as an oral suspension (20 mg/5 mL).


Official Dosing and Frequency

The medication is administered once daily at any time of the day. The standard adult starting dose is either 10 mg or 20 mg once daily, although a 40 mg starting dose is specified for patients requiring substantial LDL-C reduction (over 45%). The maximum daily dose for adults is 80 mg.

Dosage adjustments, if required, should only be made after assessing lipid levels, and generally no sooner than four weeks following the start of treatment or a previous dose change.


Administration Conditions and Special Rules

The intake instructions depend on the formulation used:

  • Tablets may be taken with or without food.
  • The oral suspension must be taken on an empty stomach (1 hour before or 2 hours after a meal) and measured with a calibrated device.

For pediatric patients (ages 10–17) with Heterozygous Familial Hypercholesterolemia, the starting dose is 10 mg once daily, with a maximum dose of 20 mg once daily. If a dose is missed by more than 12 hours, the dose should be skipped, and the regular schedule should be resumed. No dose adjustment is necessary for patients with renal impairment. Specific maximum daily dose limits (e.g., 20 mg or 40 mg) apply when Atria is co-administered with certain medications, such as specific antivirals or antibiotics.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Atria


Evidence on Preventing Cardiovascular Events (Primary Prevention)

Research into Atorvastatin was conducted primarily using large-scale Randomized Controlled Trials (RCTs), exploring patterns related to first-time cardiovascular events. These studies were designed to measure changes in the incidence of serious health events—specifically non-fatal heart attacks (myocardial infarction), fatal heart disease, and strokes—in certain high-risk adult populations. The findings from these controlled trials, often synthesized through meta-analyses, reported patterns related to the monitored outcomes. Studies consistently documented measured changes during the study period, particularly patterns related to changes in LDL-C (low-density lipoprotein cholesterol, or "bad" cholesterol).

Despite the body of evidence, long-term outcomes for these specific populations are not fully established beyond the initial trial periods. While some cohorts were tracked for ten or more years, these extended follow-up durations were limited, and post-trial changes in medication usage by participants can introduce uncertainty into the very long-term analysis.


Evidence for Management Following a Cardiovascular Event (Secondary Prevention)

Dedicated Randomized Controlled Trials were also evaluated in patients with established coronary artery disease, including those who had previously experienced a heart attack. Studies monitored outcomes linked to inflammatory states, such as patterns related to the incidence of recurrent heart attacks, non-fatal strokes, and procedures such as revascularization. Scientific reviews suggest that the research base is extensive for short- to intermediate-term follow-up.


Evidence on Managing High Cholesterol and Lipids (Hypercholesterolemia)

Atorvastatin was evaluated in short-term, controlled Randomized Controlled Trials to study the relationship with blood lipid levels in adults with various forms of primary high cholesterol. Research explored short-term changes in lipid biomarkers. The research consistently documented alterations in major lipid biomarkers, including patterns related to changes in LDL-C, Total-C, and triglycerides. Because the primary focus of these trials is on the percentage change in lipid biomarkers, which are surrogate outcomes, the research provides limited insight into long-term cardiovascular outcomes derived solely from these short-term studies.

Evidence in Specific Familial Hypercholesterolemia

Specialized research has explored the use of Atorvastatin in patients with rare, genetically-driven severe cholesterol disorders, such as Homozygous Familial Hypercholesterolemia (HoFH). These studies are often smaller, open-label trials due to the rarity of the condition. They tracked the absolute and relative changes in LDL-C in both adults and children aged 10 and older. Results apply only to the populations studied, and long-term effects on cardiovascular outcomes are not fully established given the limited number of participants.


Research Gaps and Areas of Uncertainty

One key limitation is that many studies rely on short-term changes in cholesterol levels as their main findings, which provide context but not individual predictions of long-term cardiovascular outcomes. Furthermore, evidence quality varies across studies, and comparative evidence directly assessing long-term non-cardiovascular outcomes against all other available treatments is still emerging.

Key Studies & References

  1. Clinical Guideline: Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids

Frequently Asked Questions (FAQ)

Common questions about Atria (FAQ)

Q: How quickly does Atria start working after the first dose?

A: Studies indicate that changes in lipid levels (therapeutic response) are generally observed within 2 weeks of beginning the medicine. The maximum effect is typically reached within about 4 weeks.


Q: What is the typical timeframe before Atria's full effect is noticed?

A: According to official product information, the maximum cholesterol-lowering effect (full therapeutic response) is usually achieved and maintained within 4 weeks after therapy is initiated or a dose is changed.


Q: How long do you usually have to take Atria for?

A: Atria is generally indicated for the management of a chronic process, such as high cholesterol. Official labeling indicates the medicine is intended for use as a continuous, long-term therapy, consistent with its use for chronic conditions.


Q: Does Atria cause weight gain or weight loss?

A: Regulatory documents indicate that weight gain has been reported as an uncommon adverse reaction associated with this medicine. Weight loss is not specifically mentioned in the official adverse reaction profile.


Q: What happens if you take Atria with alcohol?

A: Official warnings note that individuals who consume substantial quantities of alcohol or have a history of high alcohol intake may be at an increased risk for hepatic (liver) injury when taking this medicine.


Q: Are there any specific foods to avoid when taking Atria?

A: The consumption of excessive grapefruit juice should be avoided while taking Atria. Regulatory documents define excessive consumption as more than 1.2 liters (about 5 cups) per day, which can increase the concentration of the medicine in the plasma.


Q: Can men and women take Atria for the same reasons?

A: Yes, regulatory documents indicate that the medicine's approved uses (Indications for Use) are based on treating specific lipid conditions and cardiovascular risk factors, and not on a patient's sex.


Q: Can Atria affect your sleep schedule?

A: Official information lists insomnia (difficulty sleeping) as an uncommon adverse reaction associated with this medicine.


Q: What research has been done on the long-term effects of Atria?

A: The effects of Atria have been monitored in large clinical trials designed to assess cardiovascular outcomes for several years. While these provide significant data, the official information notes that outcomes beyond the trial periods are considered not fully established.


Q: Is it normal to feel a bit nauseous in the first few days on Atria?

A: Yes, nausea is listed as a common side effect of this medicine. Some adverse reactions are reported to appear soon after starting treatment and may be temporary, but this is not specifically stated for common effects like nausea.


Q: Can Atria affect your mood or concentration?

A: Regulatory documents indicate a potential for Central Nervous System (CNS) effects. This is supported by the listing of uncommon adverse reactions such as insomnia, which can indirectly influence concentration.


Q: Does Atria have a 'half-life' and what does that mean?

A: Yes, Atria has a half-life, which refers to the time it takes for half of the medicine to be cleared from the body. The half-life of the parent drug is about 14 hours, but the time for its intended effect to decrease is longer—between 20 and 30 hours—due to the activity of breakdown products called active metabolites.


Q: What is the main benefit Atria offers over non-drug treatments?

A: Official guidelines indicate that Atria is recommended when the response to non-pharmacologic measures (like diet alone) has been inadequate. The medicine acts as an adjunct (an addition) to a diet restricted in saturated fat and cholesterol to further assist in reducing lipid levels.


Q: Are the initial side effects of Atria temporary?

A: Some changes reported in studies, such as elevated liver enzymes (serum transaminases), appeared soon after initiation, were reported to be transient, and often resolved or improved while treatment continued.


Q: Are there any lifestyle changes recommended while taking Atria?

A: Yes, the official labeling states that therapy with Atria should be considered only one component of a plan to manage multiple cardiovascular risk factors. It is recommended as an adjunct to a diet restricted in saturated fat and cholesterol.


Q: How often do people need follow-up appointments when taking Atria?

A: The official documents recommend that lipid levels, specifically LDL-C (bad cholesterol), should be assessed as early as 4 weeks after starting the medicine or changing the dosage. The frequency of appointments is ultimately determined by the healthcare provider.


Q: Do I need to take Atria at the exact same time every day?

A: Atria tablets are intended to be taken once daily at any time of the day. Clinical studies have shown that the effectiveness of the drug in reducing cholesterol is the same regardless of the time of day it is administered.


Q: What should I do if I get an upset stomach from Atria?

A: Atria tablets may be taken with or without food. Taking the tablet with food has been noted in patient information as a way to potentially alleviate discomfort, such as an upset stomach.


Q: Can Atria be crushed or chewed, or must it be swallowed whole?

A: Regulatory information typically instructs that tablets should be swallowed whole with water. The tablets should not be crushed or chewed unless explicitly authorized by a healthcare professional.


Q: What happens in the body when Atria starts to take effect?

A: Atria works by selectively inhibiting an enzyme called HMG-CoA reductase in the liver. This action helps to suppress the body's production of cholesterol and leads to the liver removing more cholesterol from the bloodstream.


Q: Why is Atria sometimes prescribed at a lower dose initially?

A: Regulatory documents recommend a lower starting dosage (such as 10 mg or 20 mg) for adults. This approach allows healthcare providers to assess the response by measuring lipid levels after about four weeks and then adjust the dose if needed.


Q: Are there generic versions of Atria available?

A: Yes, Atria's active ingredient, atorvastatin calcium, is available in generic versions. The U.S. FDA, through resources like the Orange Book, has approved these generic atorvastatin calcium tablets in multiple strengths.


Q: Is the strength of the pill important for how Atria works?

A: Yes, dose is related to effect. Clinical studies cited in official labeling show that the cholesterol-lowering effect (reduction in LDL-C) generally increases as the dose of Atria is increased from 10 mg up to 80 mg.

How should Atria be stored and disposed of?

Storage Requirements

Atripla tablets must be stored at Controlled Room Temperature, which is 25 C (77 F). The product permits temperature excursions between 15 C and 30 C (59 F and 86 F).

To ensure proper stability and protection from moisture, the tablets must be kept in the original container and the bottle must be tightly closed with its child-resistant closure. It is necessary to keep the bottle closed with the desiccant inside and protect the medication from excessive heat and moisture. The product should be kept out of reach of children at all times.

Disposal Instructions

Disposal must follow general guidance to protect the environment. Unused or expired Atripla should be disposed of through a medicine take-back program if one is available in your community. If a take-back program is not accessible, the medication should be mixed with an undesirable substance, such as used coffee grounds or cat litter, sealed in a plastic bag, and then discarded in the household trash. Do not flush the tablets down a toilet or pour them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atria found in:

A-Z Index: